Pages that link to "Item:Q5714615"
From MaRDI portal
The following pages link to Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent (Q5714615):
Displaying 10 items.
- Bayesian models and decision algorithms for complex early phase clinical trials (Q903294) (← links)
- Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers (Q1790751) (← links)
- Multivariate Markov models for the conditional probability of toxicity in phase II trials (Q2792772) (← links)
- A Phase I Bayesian Adaptive Design to Simultaneously Optimize Dose and Schedule Assignments Both Between and Within Patients (Q2861803) (← links)
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes (Q2861956) (← links)
- Dose-Finding Based on Feasibility and Toxicity in T-cell Infusion Trials (Q3078842) (← links)
- DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses (Q6068878) (← links)
- Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics (Q6079344) (← links)
- Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens (Q6628011) (← links)
- Extending the continual reassessment method to accommodate step-up dosing in phase I trials (Q6628516) (← links)
